-+ 0.00%
-+ 0.00%
-+ 0.00%

VOYAGER DEMONSTRATES SINGLE IV DOSE OF VY1706 WELL TOLERATED, REDUCED TAU IN 6-MONTH GLP TOXICOLOGY STUDY; INITIATION OF CLINICAL TRIAL IN ALZHEIMER’S DISEASE EXPECTED H2 2026

路透·07/13/2026 12:01:00

登录查看新闻详情